{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChange": 0.0, "regularMarketTime": 1683871346, "regularMarketDayHigh": 0.56, "regularMarketDayRange": "0.56 - 0.56", "regularMarketDayLow": 0.56, "regularMarketVolume": 7580, "regularMarketPreviousClose": 0.56, "bid": 0.55, "ask": 0.57, "fullExchangeName": "Munich", "financialCurrency": "USD", "regularMarketOpen": 0.56, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.06099999, "fiftyTwoWeekLowChangePercent": 0.12224446, "fiftyTwoWeekRange": "0.499 - 1.405", "fiftyTwoWeekHighChange": -0.84499997, "fiftyTwoWeekHighChangePercent": -0.6014235, "fiftyTwoWeekLow": 0.499, "fiftyTwoWeekHigh": 1.405, "exchange": "MUN", "shortName": "NRX PHARMACEUTI.  DL-,001", "longName": "NRx Pharmaceuticals, Inc.", "messageBoardId": "finmb_319388181", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.56, "earningsTimestamp": 1684240200, "earningsTimestampStart": 1684240200, "earningsTimestampEnd": 1684240200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.56, "sharesOutstanding": 71557600, "bookValue": 0.113, "fiftyDayAverage": 0.64422, "fiftyDayAverageChange": -0.08421999, "fiftyDayAverageChangePercent": -0.13073173, "twoHundredDayAverage": 0.858255, "twoHundredDayAverageChange": -0.29825503, "twoHundredDayAverageChangePercent": -0.3475133, "marketCap": 40349292, "priceToBook": 4.9557524, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "NeuroRx, Inc.", "nameChangeDate": "2023-05-11", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1623045600000, "priceHint": 4, "symbol": "B1QB.MU"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "(484) 254-6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen H. Willard Esq.", "age": 61, "title": "CEO & Director", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 501186, "fmt": "501.19k", "longFmt": "501,186"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 65, "title": "Co-Founder, Chief Scientist Officer & Director", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": {"raw": 926008, "fmt": "926.01k", "longFmt": "926,008"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Seth L. Van Voorhees Ph.D.", "age": 61, "title": "CFO & Treasurer", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 399960, "fmt": "399.96k", "longFmt": "399,960"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Riccardo  Panicucci Ph.D.", "age": 60, "title": "Chief Technology Officer", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 220000, "fmt": "220k", "longFmt": "220,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael  Kunz", "age": 57, "title": "Gen. Counsel & Corp. Sec.", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 75, "title": "Chief Methodologist", "yearBorn": 1947, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dennis K. McBride Ph.D.", "title": "Chief Strategy Officer & Sr. Scientist", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 59, "title": "Chief Bus. Officer", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}